Thermogenesis Holdings Inc represents values of innovation, excellence, and commitment in the field of regenerative medicine. With a strong corporate philosophy focused on advancing cell and gene therapies, the company aims to revolutionize the treatment of various diseases and conditions. By harnessing cutting-edge technologies, Thermogenesis Holdings Inc is dedicated to providing high-quality solutions that enhance patient outcomes and quality of life. The company's emphasis on research, development, and collaboration with key industry players reflects its commitment to driving progress and improving healthcare worldwide.

Thermogenesis Holdings Inc is primarily present in the United States.

Thermogenesis Holdings Inc has achieved several significant milestones in its history. The company has successfully developed and brought to market innovative medical devices and technologies, establishing itself as a leader in the field of regenerative medicine. Thermogenesis Holdings Inc has achieved notable advancements in the collection and processing of stem cells, revolutionizing the industry. Additionally, the company has expanded its product portfolio and entered into strategic partnerships, further solidifying its position in the market. Thermogenesis Holdings Inc continues to drive innovation and make significant contributions to the field of regenerative medicine, positioning itself for continued growth and success.

Thermogenesis Holdings Inc, an American company, has a rich history and background in the medical technology industry. Established in 1986, the company focuses on developing and commercializing innovative cell and tissue-based products. With a strong emphasis on regenerative medicine, Thermogenesis Holdings Inc has gained expertise in designing and manufacturing advanced systems for the processing and storage of cellular therapies. The company has received multiple FDA approvals and has collaborated with renowned medical institutions worldwide. Thermogenesis Holdings Inc continues to revolutionize the field of regenerative medicine, striving to improve patient outcomes through its cutting-edge solutions.

The main competitors of Thermogenesis Holdings Inc in the market are CryoPort, Inc. and Cesca Therapeutics Inc.

Thermogenesis Holdings Inc is primarily active in the healthcare industry.

The business model of Thermogenesis Holdings Inc. revolves around the development and commercialization of innovative cell and gene therapy technologies. With a focus on regenerative medicine and immunotherapy, Thermogenesis Holdings Inc. aims to provide advanced solutions for various medical conditions. The company utilizes its proprietary platforms and expertise to enable the collection, processing, storage, and administration of cell-based therapies. By collaborating with key industry partners and utilizing cutting-edge technologies, Thermogenesis Holdings Inc. strives to revolutionize the field of regenerative medicine and contribute to patient care and well-being.

P/E-lukua ei voida tällä hetkellä laskea kohteelle Thermogenesis Holdings.

KUV:tä ei voida tällä hetkellä laskea Thermogenesis Holdings osalta.

AlleAktien Laatuscore Thermogenesis Holdings on 5/10.

Liikevaihtoa ei voida tällä hetkellä laskea yritykselle Thermogenesis Holdings.

Voitto ei voida tällä hetkellä laskea yritykselle Thermogenesis Holdings.

Thermogenesis Holdings Inc. is a company that has been operating in the health and biotechnology industry since 1986. The company's business model consists of three business areas focusing on stem cell therapy, diagnostics, and customer service. In the area of stem cell therapy, Thermogenesis Holdings Inc. offers products and services for stem cell collection, processing, and storage. The company's innovative solutions allow for the extraction, isolation, and freezing of stem cells from blood, umbilical cord, and bone marrow. These stem cells can be used in various diseases to promote healing and alleviate symptoms. In the field of diagnostics, Thermogenesis Holdings Inc. offers clinical diagnostic instruments for blood processing, such as the AXP® AutoXpress® system. These systems allow medical professionals to isolate stem cells and further develop them in clinical research. Additionally, the company also provides cell culture systems and devices for cell analysis and characterization, such as the FreezerPro® system. In addition to these two main areas, Thermogenesis Holdings Inc. also provides comprehensive customer service. The company offers a 24/7 hotline, technical support, as well as customized training and education for its customers. The main product of Thermogenesis Holdings Inc. is the CryoSeal® FS system for processing tissues and organs intended for transplantation. It is used in combination with the cell processing technology MXP®, allowing for fast and effective processing of various biological materials. From tissues to cells to organs, Thermogenesis Holdings Inc. offers a wide range of solutions. The company also operates in various other countries and has branches in Germany, France, and Finland. Along with its subsidiaries, the company serves customers worldwide. Thermogenesis Holdings Inc. is a company with a long tradition in biotechnological research and development. With its innovative products and solutions, the company has established a leading position in the industry. With a strong presence in the international market and a comprehensive customer service strategy, Thermogenesis Holdings Inc. has made a name for itself.

Thermogenesis Holdings maksaa osinkoa 0 USD, joka jaetaan erässä vuoden aikana.

Osinkoa ei voida tällä hetkellä laskea Thermogenesis Holdings:lle tai yhtiö ei maksa osinkoa.

Thermogenesis Holdings:n ISIN on US88362L1008.

Thermogenesis Holdings:n WKN on A2PUSP.

Thermogenesis Holdings:n tunnus on THMO.

Viimeisen 12 kuukauden aikana Thermogenesis Holdings maksoi osinkoa edestä. Tämä vastaa noin osinkotuottoa. Seuraavan 12 kuukauden aikana Thermogenesis Holdings maksanee ennusteiden mukaan 0 USD osingon.

Thermogenesis Holdings:n tämänhetkinen osinkotuotto on .

Thermogenesis Holdings maksaa osinkoa neljännesvuosittain. Osingot jaetaan kuukausina .

Thermogenesis Holdings maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Seuraavalle 12 kuukaudelle odotetaan 0 USD suuruisia osinkoja. Tämä vastaa 0 % osinkotuottoa.

Thermogenesis Holdings kuuluu sektoriin 'Terveys'.

Saadaksesi viimeisimmän Thermogenesis Holdings osingon 19.12.2024, jonka suuruus on 0 USD, sinun oli oltava omistanut osakkeen ennen ex-päivää, joka oli 19.12.2024.

Viimeisin osinko maksettiin 19.12.2024.

Vuonna 2023 Thermogenesis Holdings maksoi 0 USD osinkoina.

Thermogenesis Holdings:n osingot maksetaan USDssa.